EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Emmaus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026
- Market cap
- $6.03M
- P/E (TTM)
- –
- Dividend yield
- –
Emmaus Life Sciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endari - U.S. [Member] | $6.00M | $1.38M | – | – | $2.32M | $2.90M | $2.76M | – | – | $6.97M | $4.61M | – | 95.0% | +158.3% |
| Endari - International [Member] | $295.00K | $583.00K | $1.27M | $1.23M | $474.00K | $307.00K | $2.49M | – | – | $66.00K | $321.00K | – | 4.7% | -37.8% |
| Other [Member] | $22.00K | $23.00K | $30.00K | $22.00K | $20.00K | $82.00K | $236.00K | $26.00K | $162.00K | $31.00K | $85.00K | $282.00K | 0.3% | +10.0% |
| Endari [Member] | – | – | – | $2.12M | $2.80M | – | $2.76M | $5.35M | $2.34M | $7.04M | $4.93M | $10.48M | – | – |
By region
From the segment and revenue-disaggregation notes of Emmaus Life Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.